Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy
PLEASANTON, Calif., July 28, 2026 /PRNewswire/ — Aqua Medical, Inc., a clinical-stage medical technology company pioneering Endoscopic Metabolic Restoration, today announced the successful treatment of the first U.S. patient in its U.S. Food and Drug Administration (FDA)-authorized Investigational Device Exemption (IDE) clinical trial evaluating the company’s proprietary Proximal Intestinal Mucosal Ablation (PIMA) procedure for the treatment of type 2 diabetes. The landmark […]
MASS DEVICE Feature Article on Aqua Medical’s First T2D IDE Trial Patient
Aqua Medical says it has successfully treated the first type 2 diabetes patient with its proximal intestinal mucosal ablation (PIMA) procedure in an FDA investigational device exemption (IDE) trial. The clinical-stage medtech developer uses radiofrequency vapor ablation (RFVA) through a standard endoscope without fluoroscopy for the minimally-invasive, outpatient PIMA procedure in the duodenum. The FDA […]